Rifampicin Resistance Pattern of Mycobacterium Tuberculosis Infection in Tertiary Care Hospital Settings

Overview

Journal Cureus

Specialty Biomedical Engineering

Date 2024 Apr 8

PMID 38586690

Authors

Avantika Ranganathan

Durai Singh Carmelin

Raman Muthusamy

Affiliations

Soon will be listed here.

Abstract

Introduction (MTB), the causative agent of tuberculosis (TB), continues to pose a significant global health threat, with increasing concerns about antimicrobial resistance (AMR). This study aims to elucidate the AMR patterns of MTB infections in tertiary care hospital settings. Materials and methods A retrospective analysis was conducted on 138 clinical samples collected from patients attending the outpatient ward with clinically suspected MTB infections from November 2022 to April 2023 in a tertiary care hospital, Saveetha Medical College and Hospital. The study focused on the sample isolates collected from various clinical specimens, such as sputum, pus, synovial fluid, wound swabs, and other forms of samples from the patients. The samples were processed and analyzed with routine microbiological confirmation tests using standard laboratory methods such as staining and culture. Further, the samples were subjected to a GeneXpert MTB/RIF assay to assess the resistance to Rifampicin (RIF). The results were interpreted, analyzed using standard statistical methods, and presented. Results The findings revealed marked resistance of the clinical isolate MTB to TIF, with positive and negative results through various peak levels shown by GeneXpert. Out of the 138 samples screened by GeneXpert for resistance, 14 samples were found to be positive (10.14%). Resistance to the first-line drug, namely RIF, was observed in the study, raising concerns about the effectiveness of standard tuberculosis treatment regimens followed in the country. Conclusion This study implies the urgency of monitoring and addressing AMR in MTB infections in tertiary care hospital settings. The emergence of resistance to even the first-line drugs necessitates continuous surveillance, the implementation of appropriate diagnostic strategies, and the development of effective treatment protocols. A comprehensive understanding of the AMR landscape in tuberculosis is crucial for optimizing therapeutic interventions, preventing the spread of drug-resistant strains, and ultimately curbing the global burden of tuberculosis.

References

Prasad R, Gupta N, Banka A . Multidrug-resistant tuberculosis/rifampicin-resistant tuberculosis: Principles of management. Lung India. 2018; 35(1):78-81. PMC: 5760876. DOI: 10.4103/lungindia.lungindia_98_17. View

Idigoras P, Beristain X, Iturzaeta A, Vicente D, Perez-Trallero E . Comparison of the automated nonradiometric Bactec MGIT 960 system with Löwenstein-Jensen, Coletsos, and Middlebrook 7H11 solid media for recovery of mycobacteria. Eur J Clin Microbiol Infect Dis. 2000; 19(5):350-4. DOI: 10.1007/s100960050492. View

Karthek V, Bhilare P, Hadgaonkar S, Kothari A, Shyam A, Sancheti P . Gene Xpert/MTB RIF assay for spinal tuberculosis- sensitivity, specificity and clinical utility. J Clin Orthop Trauma. 2021; 16:233-238. PMC: 7919860. DOI: 10.1016/j.jcot.2021.02.006. View

Campbell E, Korzheva N, Mustaev A, Murakami K, Nair S, Goldfarb A . Structural mechanism for rifampicin inhibition of bacterial rna polymerase. Cell. 2001; 104(6):901-12. DOI: 10.1016/s0092-8674(01)00286-0. View

Patel J, Upadhyay M, Kundnani V, Merchant Z, Jain S, Kire N . Diagnostic Efficacy, Sensitivity, and Specificity of Xpert MTB/RIF Assay for Spinal Tuberculosis and Rifampicin Resistance. Spine (Phila Pa 1976). 2019; 45(3):163-169. DOI: 10.1097/BRS.0000000000003225. View

Fatima S, Kumari A, Das G, Dwivedi V . Tuberculosis vaccine: A journey from BCG to present. Life Sci. 2020; 252:117594. DOI: 10.1016/j.lfs.2020.117594. View

Peloquin C, Davies G . The Treatment of Tuberculosis. Clin Pharmacol Ther. 2021; 110(6):1455-1466. DOI: 10.1002/cpt.2261. View

Mushtaq F, Raza S, Ahmad A, Aslam H, Adeel A, Saleem S . Antimicrobial drug resistant features of Mycobacterium tuberculosis associated with treatment failure. PLoS One. 2023; 18(10):e0293194. PMC: 10602240. DOI: 10.1371/journal.pone.0293194. View

Noordhoek G, Mulder S, Wallace P, van Loon A . Multicentre quality control study for detection of Mycobacterium tuberculosis in clinical samples by nucleic amplification methods. Clin Microbiol Infect. 2004; 10(4):295-301. DOI: 10.1111/j.1198-743X.2004.00825.x. View

10.

Dantas A . Antimicrobial resistance. Mol Microbiol. 2022; 117(5):959-960. DOI: 10.1111/mmi.14912. View

11.

Sharma S, Ryan H, Khaparde S, Sachdeva K, Singh A, Mohan A . Index-TB guidelines: Guidelines on extrapulmonary tuberculosis for India. Indian J Med Res. 2017; 145(4):448-463. PMC: 5663158. DOI: 10.4103/ijmr.IJMR_1950_16. View

12.

Telenti A, Imboden P, Marchesi F, Schmidheini T, Bodmer T . Direct, automated detection of rifampin-resistant Mycobacterium tuberculosis by polymerase chain reaction and single-strand conformation polymorphism analysis. Antimicrob Agents Chemother. 1993; 37(10):2054-8. PMC: 192227. DOI: 10.1128/AAC.37.10.2054. View

13.

Pai M, Behr M . Latent Mycobacterium tuberculosis Infection and Interferon-Gamma Release Assays. Microbiol Spectr. 2016; 4(5). DOI: 10.1128/microbiolspec.TBTB2-0023-2016. View

14.

Mokrousov I, Otten T, Vyshnevskiy B, Narvskaya O . Allele-specific rpoB PCR assays for detection of rifampin-resistant Mycobacterium tuberculosis in sputum smears. Antimicrob Agents Chemother. 2003; 47(7):2231-5. PMC: 161874. DOI: 10.1128/AAC.47.7.2231-2235.2003. View

15.

Ramachandran G, Swaminathan S . Safety and tolerability profile of second-line anti-tuberculosis medications. Drug Saf. 2015; 38(3):253-69. DOI: 10.1007/s40264-015-0267-y. View

16.

Quenard F, Fournier P, Drancourt M, Brouqui P . Role of second-line injectable antituberculosis drugs in the treatment of MDR/XDR tuberculosis. Int J Antimicrob Agents. 2017; 50(2):252-254. DOI: 10.1016/j.ijantimicag.2017.01.042. View

17.

Mohamed M, Ali O, Osman A, Abatcha M, Ahmed A, Ali A . Assessment of drug-susceptible and multidrug-resistant tuberculosis (MDR-TB) in the Central Region of Somalia: A 3-year retrospective study. PLOS Glob Public Health. 2023; 3(9):e0002319. PMC: 10484424. DOI: 10.1371/journal.pgph.0002319. View

18.

Rachow A, Zumla A, Heinrich N, Rojas-Ponce G, Mtafya B, Reither K . Rapid and accurate detection of Mycobacterium tuberculosis in sputum samples by Cepheid Xpert MTB/RIF assay--a clinical validation study. PLoS One. 2011; 6(6):e20458. PMC: 3126807. DOI: 10.1371/journal.pone.0020458. View

19.

Bourzac K . Infectious disease: Beating the big three. Nature. 2014; 507(7490):S4-7. DOI: 10.1038/507s4a. View

20.

Dockrell H, Butkeviciute E . Can what have we learnt about BCG vaccination in the last 20 years help us to design a better tuberculosis vaccine?. Vaccine. 2021; 40(11):1525-1533. PMC: 8899334. DOI: 10.1016/j.vaccine.2021.01.068. View